Opko Health Inc. Forecasted to Earn Q3 2016 Earnings of ($0.01) Per Share (OPK)
Opko Health Inc. (NYSE:OPK) – Oppenheimer Holdings issued their Q3 2016 earnings estimates for Opko Health in a research report issued to clients and investors on Sunday. Oppenheimer Holdings analyst M. Ho expects that the firm will earn ($0.01) per share for the quarter. Oppenheimer Holdings has a “Hold” rating on the stock. Oppenheimer Holdings also issued estimates for Opko Health’s Q4 2016 earnings at ($0.02) EPS, FY2016 earnings at ($0.03) EPS, FY2017 earnings at $0.03 EPS, FY2018 earnings at $0.61 EPS, FY2019 earnings at $1.17 EPS and FY2020 earnings at $1.85 EPS.
Opko Health (NYSE:OPK) last posted its earnings results on Monday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.05. The business had revenue of $357.10 million for the quarter, compared to analyst estimates of $324.11 million. Opko Health’s revenue was up 742.2% compared to the same quarter last year. During the same period last year, the business earned ($0.09) EPS.
A number of other equities research analysts have also weighed in on the company. Jefferies Group reaffirmed a “hold” rating on shares of Opko Health in a report on Wednesday, August 17th. JPMorgan Chase & Co. set a $14.00 price target on Opko Health and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Deutsche Bank AG decreased their price target on Opko Health from $11.00 to $10.00 and set a “hold” rating on the stock in a research note on Thursday, June 16th. Standpoint Research boosted their price target on Opko Health from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, June 21st. Finally, Zacks Investment Research raised Opko Health from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. Five equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Opko Health currently has a consensus rating of “Buy” and an average target price of $13.20.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/opko-health-inc-forecasted-to-earn-q3-2016-earnings-of-0-01-per-share-opk.html
Opko Health (NYSE:OPK) traded down 1.501% during midday trading on Wednesday, reaching $9.515. The company’s stock had a trading volume of 877,380 shares. The firm’s 50-day moving average price is $10.06 and its 200-day moving average price is $10.09. Opko Health has a 52 week low of $7.12 and a 52 week high of $11.85. The stock has a market capitalization of $5.24 billion and a PE ratio of 39.812.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Commonwealth Equity Services Inc increased its position in shares of Opko Health by 4.6% in the first quarter. Commonwealth Equity Services Inc now owns 56,358 shares of the company’s stock valued at $586,000 after buying an additional 2,462 shares during the period. Aperio Group LLC increased its position in shares of Opko Health by 67.1% in the first quarter. Aperio Group LLC now owns 63,042 shares of the company’s stock valued at $655,000 after buying an additional 25,312 shares during the period. Virginia Retirement System acquired a new position in shares of Opko Health during the first quarter valued at $510,000. Teachers Advisors Inc. increased its position in shares of Opko Health by 3.6% in the first quarter. Teachers Advisors Inc. now owns 325,172 shares of the company’s stock valued at $3,379,000 after buying an additional 11,403 shares during the period. Finally, BlackRock Inc. increased its position in shares of Opko Health by 239.6% in the first quarter. BlackRock Inc. now owns 36,005 shares of the company’s stock valued at $375,000 after buying an additional 25,403 shares during the period.
In other Opko Health news, CEO Phillip Md Et Al Frost purchased 24,800 shares of the business’s stock in a transaction on Monday, October 10th. The stock was bought at an average cost of $9.82 per share, for a total transaction of $243,536.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $30,137,098.82. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
About Opko Health
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.